Eli Lilly and Company has announced plans to invest more than USD 1 billion over the next several years to expand its contract manufacturing footprint in India, aimed at enhancing global access to its innovative medicines. The investment underscores Lilly’s commitment to strengthening its manufacturing and supply capabilities to support its growing product portfolio.

As part of this initiative, the company will establish a new manufacturing and quality hub in Hyderabad, designed to provide advanced technical expertise and oversight for its contract manufacturing network across India. Recruitment for the new facility will begin immediately, with opportunities for engineers, chemists, analytical scientists, quality control and assurance experts, and management professionals. The initiative also reflects Lilly’s strategy to harness India’s skilled scientific and technical talent to fuel its global manufacturing expansion.

Since 2020, Lilly has invested over USD 55 billion globally in new facilities and expansions to support its pipeline of potential treatments for diabetes, obesity, Alzheimer’s disease, cancer, and autoimmune disorders, while preparing for the medicines of the future.

Telangana Chief Minister A. Revanth Reddy welcomed the move, noting, “Lilly’s continued expansion in Hyderabad highlights the city’s emergence as a powerhouse in global healthcare innovation. From its innovation and technology site to a new manufacturing collaboration and quality hub, Lilly is reinforcing Telangana’s position as a preferred destination for advanced healthcare investments.”

Sridhar Babu, Minister for Information Technology, Electronics & Communications, Industries & Commerce, and Legislative Affairs, added, “Lilly’s expansion demonstrates Telangana’s dynamic industrial landscape and its growing role in global healthcare manufacturing. The state’s focus on technology-led infrastructure and ease of doing business continues to attract global leaders, particularly in life sciences.”

Nivruti Rai, Managing Director & CEO of Invest India, Ministry of Commerce & Industry, said, “Lilly’s investment underscores India’s emergence as a global manufacturing and innovation hub. This partnership highlights confidence in India’s talent, infrastructure, and business-friendly environment, while advancing Lilly’s mission to transform healthcare worldwide.”

Patrik Jonsson, Executive Vice President and President, Lilly International, commented, “We are making significant investments globally to expand our manufacturing and supply capacity, ensuring patients have access to the medicines they need. Partnering with trusted manufacturers in India strengthens our ability to deliver high-quality, life-changing medicines at scale. This investment reflects our confidence in India’s growing capabilities within our global network.”

With a long-standing presence in India, including commercial operations in Gurugram and innovation-focused sites in Bengaluru and Hyderabad, Eli Lilly continues to deepen its roots in the country—aligning its global vision of turning science into healing and making life better for people around the world.